Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022007136 - COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER

Publication Number WO/2022/007136
Publication Date 13.01.2022
International Application No. PCT/CN2020/109969
International Filing Date 19.08.2020
IPC
A61K 31/7034 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
C07H 15/203 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
20Carbocyclic rings
203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 诺未科技(北京)有限公司 NEWISH TECHNOLOGY (BEIJING) CO., LTD. [CN]/[CN]
Inventors
  • 齐海龙 QI, Hailong
  • 王晓芳 WANG, Xiaofang
  • 孙忠杰 SUN, Zhongjie
Agents
  • 北京集佳知识产权代理有限公司 UNITALEN ATTORNEYS AT LAW
Priority Data
202010643576.506.07.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER
(FR) COMPOSITION ET SON UTILISATION DANS LA PRÉPARATION D'UN MÉDICAMENT DESTINÉ AU TRAITEMENT D'UN CANCER
(ZH) 组合物及其在制备治疗癌症的药物中的应用
Abstract
(EN) A composition, comprising a compound represented by formula I or a pharmaceutical salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor. On the basis of an inhibitory effect of the tyrosine kinase activity inhibitor targeting receptor tyrosine kinases such as VEGFR and EGFR, in vivo and in vitro antitumor tests show that a medication combination of sotagliflozin and the tyrosine kinase activity inhibitor has a synergistic inhibitory effect on tumors. The combination of the two medications has a more significant effect than a single medication.
(FR) L'invention concerne une composition comprenant un composé représenté par la formule I ou un sel, un dimère ou un trimère pharmaceutique de celui-ci, et un inhibiteur de l'activité des tyrosine kinases. Sur la base d'un effet inhibiteur de l'inhibiteur de l'activité des tyrosine kinases ciblant les tyrosine kinases réceptrices telles que les VEGFR et EGFR, des tests antitumoraux in vivo et in vitro montrent qu'une association médicamenteuse de sotagliflozine et de l'inhibiteur de l'activité des tyrosine kinases possède un effet inhibiteur synergique sur les tumeurs. L'association des deux médicaments présente un effet davantage significatif qu'un seul médicament.
(ZH) 含有式I化合物或其可药用盐、二聚体或三聚体和酪氨酸激酶活性抑制剂的组合物。基于酪氨酸激酶活性抑制剂靶向VEGFR,EGFR等受体酪氨酸激酶的抑制的作用,通过体内、体外抗肿瘤试验表明索格列净与酪氨酸激酶活性抑制剂联合用药可以对肿瘤产生协同抑制作用。两药联用的效果显著由于单一药物。
Related patent documents
EP2020886183This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau